Paramesh Anil S, Grosskreutz Celia, Florman Sander S, Gondolesi Gabriel E, Sharma Sanjay, Kaufman Stuart S, Fishbein Thomas M
The Recanati/Miller Transplantation Institute, Division of Intestinal Transplantation, The Mount Sinai School of Medicine, New York, New York, USA.
Transplantation. 2004 Jan 15;77(1):129-31. doi: 10.1097/01.TP.0000092522.36410.D0.
Calcineurin inhibitor-induced thrombotic microangiopathy (TMA) has been described in up to 14% of solid-organ transplant recipients. Sirolimus has recently been described in two reports in association with TMA. Sirolimus is known to potentiate cyclosporine-induced nephrotoxicity, but such effect has not been shown with tacrolimus. We report two intestinal transplant patients who developed TMA while on a tacrolimus and sirolimus immunosuppressive regimen. This syndrome appeared soon after institution of or increase in sirolimus dosage and improved only after this medication was discontinued.
钙调神经磷酸酶抑制剂诱导的血栓性微血管病(TMA)在高达14%的实体器官移植受者中有所报道。西罗莫司最近在两篇报告中被描述与TMA有关。已知西罗莫司会增强环孢素诱导的肾毒性,但他克莫司尚未显示出这种作用。我们报告了两名肠道移植患者,他们在接受他克莫司和西罗莫司免疫抑制方案时发生了TMA。这种综合征在西罗莫司剂量开始使用或增加后不久出现,仅在停用该药物后才有所改善。